Cryo-Cell International received NYSE American acceptance of its compliance plan on May 6, 2026, granting until September 9, 2027 to address listing deficiencies while shares remain listed and traded.
Key takeaways
NYSE Regulation accepted Company's compliance plan submitted April 8, 2026, for stockholders’ deficit and net losses.
Plan period extends through September 9, 2027, with common stock continuing to trade on NYSE American.
Subject to ongoing review and adherence to plan initiatives during the period.
No assurance of regaining compliance by deadline; failure may trigger delisting proceedings.
Non-compliance stemmed from Section 1003(a): deficit as of Nov 30, 2025, and losses in two of three recent fiscal years.